Altasciences to Conduct Clinical Trial for Opioid Use Disorder under NIH Funding
Altasciences has been selected by Indivior PLC to conduct "A Phase I, Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of INDV-2000 (C4X_3256) Under Fasting and Fed Conditions in Healthy Volunteers".
Altasciences Conducts Successful First-in-Human Trial for Acurx Pharmaceuticals' Novel Antibiotic to Treat C. Difficile Infection
On behalf of the sponsor, Acurx Pharmaceuticals, Altasciences is proud to have successfully completed the clinical conduct, data management, and SAS programming for ACX-362E, a novel, oral antibacterial agent for the treatment of Clostridioides difficile infection (CDI), an acute, serious, potentially life-threatening, intestinal infection.
Altasciences Welcomes Two New Veterinarians to their Preclinical Team
Altasciences is pleased to be adding Drs. Andrew Gorman and Sylvia West to their team of clinical veterinarians. Both will play key roles in providing clinical care, research, and surgical support, as well as insight into protocol development.
Lynne LeSauteur, PhD, Joins Altasciences as Vice President, Immunochemistry and Immunology
Altasciences is pleased to announce the addition of Dr. Lynne LeSauteur, PhD, to their bioanalytical management team, responsible for the Bioanalytical Services department in the U.S.A. and the Ligand Binding team in Canada.
Altasciences’ CEO Chris Perkin Recognized as PharmaVoice Red Jacket Honoree
Altasciences is proud to announce that CEO Chris Perkin has been recognized as a 2019 Red Jacket honoree.
Altasciences Leads Research on Chemical Nerve Agent Therapeutic from Preclinical to Clinical Phase I
Altasciences announced today that they have been selected by Leidos Health to guide and support the development of RAP-103 peptide as a chemical nerve agent therapeutic on behalf of the Medical CBRN Defense Consortium and funded by the Defense Threat Reduction Agency (DTRA).
Altasciences and WuXi AppTec Enter Into Collaboration for WIND Projects
Altasciences will provide its full-service solutions, including clinical pharmacology, first-in-human and proof-of-concept trials, program management, medical writing, biostatistics, and data management to support and conduct comprehensive early phase clinical services for WuXi AppTec’s multiple ongoing WIND programs.
Altasciences Wins Most Successful Early Phase Research (Preclinical & Phase I) at the 2019 CARE Awards
Altasciences won in the Most Successful Early Phase Research (Preclinical & Phase I) category at the 2019 Clinical and Research Excellence (CARE) Awards. The award win was announced during a ceremony presented by Ben Nemzer at the Hyatt Regency Boston, US on May 2, 2019.
Altasciences Receives CRO Leadership Award in Five Categories
For the 2019 CRO Leadership Awards, Life Science Leader magazine once again teamed up with Industry Standard Research (ISR) to determine the award recipients.